The store will not work correctly in the case when cookies are disabled.
Biological Data
Biological description | JMJD3 and UTX histone demethylase inhibitor,GSK J1 prodrug. Cell permeable. Reduces macrophage proinflammatory cytokine production. Improves survival in Cardio-facio-cutaneous (CFC) syndrome in mice and inhibits growth of T-cell acute lymphoblastic leukaemia cancer cells. |
Solubility & Handling
Storage instructions | Room temperature |
Solubility overview | Soluble in DMSO (100mM) or ethanol (100mM) |
Important | This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use. |
Chemical Data
Chemical name | N-[2-(2-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-alanin e ethyl ester |
Chemical structure | |
Molecular Formula | C24H27N5O2 |
PubChem identifier | 71729975 |
SMILES | O=C(CCNC1=NC(C2=CC=CC=N2)=NC(N3CCC(C=CC=C4)=C4CC3)=C1)OCC |
InChiKey | WBKCKEHGXNWYMO-UHFFFAOYSA-N |
References for GSK J4
References are publications that support the biological activity of the product
-
New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome.
Inoue S et al (2014) Hum Mol Genet 23(24) : 6553-66. -
Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia.
Ntziachristos P et al (2014) Nature 514(7523) : 513-7. -
A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.
Kruidenier L et al (2012) Nature 488(7411) : 404-8.
JMJD3 / UTX Histone demethylase inhibitor